rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CMPS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      COMPASS Pathways (CMPS) Could Be 62% Undervalued As FDA Filing Sharpens The Case
      Nov 12Yahoo FinanceCMPS
      Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
      Nov 12Yahoo FinanceCMPS
      EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
      Nov 12ReutersCMPS
      COMPASS Pathways at Stifel 2026 Healthcare Conference 2026: launch prep advances
      Nov 11Investing.comCMPSSF
      Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
      Nov 11Yahoo FinanceCMPSJEF
      Compass Pathways PLC (CMPS) (Q3 2026) Earnings Call Highlights: $444 Million Cash Runway, FDA ...
      Nov 11Yahoo FinanceCMPS
      DEA looks to increase legal psychedelics production for medical research (CMPS:NASDAQ)

      The DEA seeks to raise 2027 research quotas to 33,296 grams of MDMA and 12,002 grams of ibogaine, drastically up from 2026 levels. Read more here.

      Nov 10Seeking AlphaCMPS
      Compass Pathways stock gains on FDA filing for depression drug

      Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) shares rose 4.5% on Monday after the company completed its New Drug Application submission to the FDA for COMP360 psilocybin to treat treatment-resistant depression.

      Nov 9Yahoo FinanceCMPS
      Jefferies reiterates Buy on Compass Pathways stock on TRD approval
      Nov 9Investing.comCMPSJEF
      Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
      Nov 9Yahoo FinanceCMPS
      Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 5Yahoo FinanceCMPS
      Is COMPASS Pathways (CMPS) Pricing In Too Much On Book Value?
      Nov 5Yahoo FinanceCMPS
      Compass Pathways stock price target maintained at $21 by RBC Capital
      Nov 4Investing.comCMPS
      Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th

      LONDON & JERSEY CITY, N.J., November 04, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET.

      Nov 4Yahoo FinanceCMPSSF
      Stifel reiterates Compass Pathways stock rating amid competition
      Nov 4Investing.comCMPS
      How Investors May Respond To COMPASS Pathways (CMPS) Smaller Loss And FDA Progress

      COMPASS Pathways reported third quarter 2026 results with a net loss of US$9.83 million, compared with US$137.72 million in the same period a year earlier, and a lower basic loss per share from continuing operations. The firm is pairing this shrinking quarterly loss with ongoing work to complete its FDA submission for COMP360. This approach tightens the link between its cash burn, trial progress and the potential timing of a first commercial depression treatment. We will now look at how...

      Nov 4Yahoo FinanceCMPS
      Compass Pathways: 3 Key Takeaways for Long-Term Investors
      Nov 4Yahoo FinanceCMPS
      Oppenheimer reiterates Compass Pathways stock rating on NDA filing
      Nov 3Investing.comCMPS
      Compass Pathways stock maintained at Buy by TD Cowen ahead of NDA filing
      Nov 3Investing.comCMPS
      Compass Pathways Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceCMPS
      Compass Pathways stock rating reiterated at Buy by BTIG
      Nov 3Investing.comCMPS
      Stifel reiterates Compass Pathways stock rating on NDA progress
      Nov 3Investing.comCMPS
      Earnings call transcript: COMPASS Pathways beats Q3 2026 loss estimate
      Nov 3Investing.comCMPS
      COMPASS Pathways stock rebounds after earnings (CMPS:NASDAQ)

      Compass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes FDA filings first. Read more here.

      Nov 3Seeking AlphaCMPS
      Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027
      Nov 3Yahoo FinanceCMPS
      CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears
      Nov 2Yahoo FinanceCMPS
      New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

      LONDON & JERSEY CITY, N.J., November 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing t

      Nov 2Yahoo FinanceCMPS
      COMPASS Pathways (CMPS) Could Be 50% Below Fair Value After NEI Congress Focus
      Oct 29Yahoo FinanceCMPS
      Compass Pathways earnings on deck as FDA approval looms
      Oct 28Investing.comCMPS
      Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
      Oct 28Yahoo FinanceCMPS
      Compass Pathways: A Compelling Opportunity In A Large And Underserved Market (NASDAQ:CMPS)
      Oct 28Seeking AlphaCMPS
      Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
      Oct 27Yahoo FinanceCMPS
      B.Riley reiterates Buy on Compass Pathways stock, $22 target
      Oct 26Investing.comCMPSRILYRILYGRILYLRILYNRILYTRILYZ
      After a long, strange trip, this CEO is close to taking a psilocybin pill to market

      Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.

      Oct 25Business InsiderCMPS
      COMPASS Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales (NASDAQ:CMPS)
      Oct 21Seeking AlphaCMPS
      Why is Compass Pathways stock climbing today?
      Oct 20Investing.comCMPS
      COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results
      Oct 18Yahoo FinanceCMPS
      Compass Pathways announces first TRD awareness day in U.S.
      Oct 14Investing.comCMPS
      Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
      Oct 14Yahoo FinanceCMPS
      Cathie Wood’s ARK sells stock in Personalised Inc, buys Compass Pathways
      Oct 13Investing.comCMPS
      Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript - Compass Pathways (NASDAQ:CMPS)

      Compass Pathways (NASDAQ:CMPS) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive

      Oct 8BenzingaCMPS
      Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LONDON & NEW YORK, October 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and re

      Oct 2Yahoo FinanceCMPS
      COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress

      COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current valuation. Recent trading tells a mixed story for COMPASS Pathways. The share price fell around 4% over the last day and is down about 10% over the past week, yet the year to date share price return is close to 90% and the 1 year total shareholder return is roughly 116%. That combination suggests...

      Oct 1Yahoo FinanceCMPS
      Compass Pathways Appoints Kelley Boucher as Chief People Officer

      LONDON & NEW YORK, September 30, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will overse

      Sep 30Yahoo FinanceCMPS
      Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

      Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling. Speaking at T

      Sep 25Yahoo FinanceCMPS
      COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk
      Sep 23Investing.comCMPS
      Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
      Sep 22Yahoo FinanceCMPS
      Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

      Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global

      Sep 22Yahoo FinanceCMPS
      Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

      Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027. Speaking

      Sep 22Yahoo FinanceCMPS
      COMPASS Pathways at Deutsche Bank summit: launch nears for COMP360
      Sep 17Investing.comCMPS

      This is the newest page. Registered accounts read further back.